Regulation of Inflammation- and Angiogenesis-related Gene Expression in Breast Cancer Cells and Co-cultured Macrophages
Background: Tumor-associated macrophages (TAMs) secrete key modifiers of tumor progression and their modification has been proposed as a therapeutic strategy. Phenotypic changes that may render TAMs selectively vulnerable to anti-cancer agents were examined. Materials and Methods: Gene arrays, rever...
Gespeichert in:
Veröffentlicht in: | Anticancer research 2008-07, Vol.28 (4B), p.2093-2099 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background: Tumor-associated macrophages (TAMs) secrete key modifiers of tumor progression and their modification has been
proposed as a therapeutic strategy. Phenotypic changes that may render TAMs selectively vulnerable to anti-cancer agents were
examined. Materials and Methods: Gene arrays, reverse transcription-polymerase chain reaction and Western blotting were used
to study inflammation- and angiogenesis-related gene expression in co-cultured breast cancer cells and macrophages and to
determine how their interactions were affected by tamoxifen and aspirin. Results: MCF-7 (mammary adenocarcinoma) cells down-regulated
macrophage migration inhibitory factor (MIF), but tamoxifen-pretreated MCF-7 cells up-regulated MIF in co-cultured macrophages.
Two molecular variants of MIF were observed in the co-cultured MCF-7 cells. Aspirin induced IL-10 expression in the macrophages,
MCF-7 and tamoxifen-pretreated MCF-7 cells. Aspirin-pretreated macrophages potently induced IL-10 expression in the MCF-7
cells. Conclusion: Because MIF is a determinant of the M1 macrophage activation state, the MCF-7-induced ablation of MIF in
TAMs is suggestive of partial M2 polarization. Tamoxifen modulates MCF-7 regulation of TAM gene expression and aspirin alters
macrophage regulation of MCF-7 gene expression. |
---|---|
ISSN: | 0250-7005 1791-7530 |